MX2021001578A - Proteina asociada a crispr novedosa y uso de la misma. - Google Patents

Proteina asociada a crispr novedosa y uso de la misma.

Info

Publication number
MX2021001578A
MX2021001578A MX2021001578A MX2021001578A MX2021001578A MX 2021001578 A MX2021001578 A MX 2021001578A MX 2021001578 A MX2021001578 A MX 2021001578A MX 2021001578 A MX2021001578 A MX 2021001578A MX 2021001578 A MX2021001578 A MX 2021001578A
Authority
MX
Mexico
Prior art keywords
associated protein
novel crispr
crispr
seq
acid sequence
Prior art date
Application number
MX2021001578A
Other languages
English (en)
Inventor
Sunghwa Choe
Dong Wook Kim
Han Seong Kim
Jongjin Park
Jiyoung Yoon
Original Assignee
G Flas Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Flas Life Sciences filed Critical G Flas Life Sciences
Publication of MX2021001578A publication Critical patent/MX2021001578A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una proteína asociada a CRISPR novedosa y un uso de la misma. Una proteína representada por una secuencia de aminoácidos de SEQ ID NO: 1 o SEQ ID NO: 3, de conformidad con la presente invención, presenta la actividad de endonucleasas, que reconocen y escinden una secuencia de ácido nucleico intracelular unida a un ARN de guía. Por lo tanto, una proteína asociada a CRISPR novedosa de la invención puede usarse como una nucleasa diferente para la edición del genoma, en un sistema CRISPR-Cas.
MX2021001578A 2018-08-09 2019-08-09 Proteina asociada a crispr novedosa y uso de la misma. MX2021001578A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180093336 2018-08-09
PCT/KR2019/010110 WO2020032711A1 (ko) 2018-08-09 2019-08-09 신규한 crispr 연관 단백질 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2021001578A true MX2021001578A (es) 2021-06-15

Family

ID=69415629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001578A MX2021001578A (es) 2018-08-09 2019-08-09 Proteina asociada a crispr novedosa y uso de la misma.

Country Status (15)

Country Link
US (1) US20210292722A1 (es)
EP (1) EP3835418A4 (es)
JP (1) JP2021532819A (es)
KR (2) KR102096592B1 (es)
CN (1) CN112567031A (es)
AU (1) AU2019319377A1 (es)
BR (1) BR112021002476A2 (es)
CA (1) CA3109105A1 (es)
EA (1) EA202190454A1 (es)
IL (1) IL280631A (es)
MX (1) MX2021001578A (es)
PH (1) PH12021550256A1 (es)
SG (1) SG11202101227TA (es)
WO (1) WO2020032711A1 (es)
ZA (1) ZA202101250B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CA3109083A1 (en) 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
KR102497690B1 (ko) * 2020-09-22 2023-02-10 (주)지플러스생명과학 신규한 crispr 연관 단백질 및 이의 용도
US20230374478A1 (en) * 2020-09-22 2023-11-23 G Flas Life Sciences Modified cas12a protein and use thereof
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3325622B1 (en) * 2015-07-25 2023-06-07 Frost, Habib A system, device and a method for providing a therapy or a cure for cancer and other pathological states
EP3374494A4 (en) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE FOR GENE THERAPY
KR102093570B1 (ko) * 2015-12-04 2020-03-25 카리부 바이오사이언시스 인코포레이티드 조작된 핵산 표적화 핵산
WO2017099494A1 (ko) * 2015-12-08 2017-06-15 기초과학연구원 Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도
US20190264186A1 (en) * 2016-01-22 2019-08-29 The Broad Institute Inc. Crystal structure of crispr cpf1
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
CA3026112A1 (en) * 2016-04-19 2017-10-26 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
US20190330659A1 (en) * 2016-07-15 2019-10-31 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
EP3526326A4 (en) * 2016-10-12 2020-07-29 The Regents of The University of Colorado, A Body Corporate NEW MODIFIED AND CHEMERICAL NUCLEASES
KR20180018466A (ko) * 2017-11-10 2018-02-21 주식회사 툴젠 면역세포의 면역조절 유전자의 활성 조절을 위한 조성물 및 그 용도

Also Published As

Publication number Publication date
EA202190454A1 (ru) 2021-04-22
BR112021002476A2 (pt) 2021-07-27
AU2019319377A1 (en) 2021-03-11
WO2020032711A1 (ko) 2020-02-13
KR20200018364A (ko) 2020-02-19
JP2021532819A (ja) 2021-12-02
EP3835418A1 (en) 2021-06-16
US20210292722A1 (en) 2021-09-23
KR20200018345A (ko) 2020-02-19
ZA202101250B (en) 2022-09-28
KR102096604B1 (ko) 2020-04-02
IL280631A (en) 2021-03-25
CN112567031A (zh) 2021-03-26
SG11202101227TA (en) 2021-03-30
CA3109105A1 (en) 2020-02-13
PH12021550256A1 (en) 2021-11-03
KR102096592B1 (ko) 2020-04-02
EP3835418A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
PH12021550256A1 (en) Novel crispr-associated protein and use thereof
MX2020004578A (es) Composiciones de casz y metodos de uso.
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
WO2019006471A3 (en) NOVEL CRISPR RNA TARGETING ENZYMES, SYSTEMS AND USES THEREOF
SG10201805815YA (en) Rna-guided gene drives
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
ZA202002094B (en) Trispecific proteins and methods of use
MX2019003678A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
MX2019003674A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
WO2014202616A3 (en) Rasamsonia gene and use thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
WO2015191693A3 (en) Method for gene editing
MX2018005392A (es) Acidos nucleicos modificados dirigidos a acidos nucleicos.
BR112015023489A2 (pt) uso de rnas-guia truncads (tru - grnas) para aumentar a especificidade de edição de genoma com rna guiado
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
MX2019006475A (es) Sistemas y métodos para dirección con arn guía puntual (arngp) de adn endógeno y fuente.
MX2018010288A (es) Sistema de transposon y metodos de uso.
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MX2022005119A (es) Metodos de reduccion de olor.
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
EA201792344A1 (ru) Ген мужской стерильности пшеницы wms и его промотор специфичной для пыльника экспрессии и их применение
ZA202202628B (en) Novel crispr dna targeting enzymes and systems
AU2018280528A8 (en) Method for improving transformation efficiency of plant and method for transforming plant
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.